ArticleBMC complementary medicine and therapies2025
Evaluation of the antibacterial efficacy of combinations of Garcinia mangostana, Curcuma comosa, and Acanthus ebracteatus for acne vulgaris treatment: in Silico and in vitro validation.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rebalancing the Skin: The Microbiome, Acne Pathogenesis, and the Future of Natural and Synthetic Therapies.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acne vulgaris (AV) is a common, long-lasting skin condition characterized by inflammation that is frequently linked to the bacteria Cutibacterium acnes (C. acnes) and Staphylococcus spp. Conventional medicines face difficulties, such as bacterial resistance, in treating acne vulgaris, highlighting the need for new treatment approaches. In this study, we investigated the antibacterial activity of three medicinal plants, Garcinia mangostana (GM), Curcuma comosa (CC), and Acanthus ebracteatus (AE), which are traditionally used to treat different illnesses because of their antibacterial, antioxidant, and anti-inflammatory properties. We utilized a mix of in silico, in vitro, and molecular dynamics (MD) techniques to assess their abilities to treat skin breakouts. We found that the active ingredients in these herbs significantly interact with several bacterial and human inflammatory proteins. Specifically, the herbal components strongly bind to the bacterial enzyme topoisomerase II alpha (TOP2α), which is fundamental for bacterial DNA replication and repair, as well as to human nuclear factor kappa B subunit 1 (NFκB1), which is a vital marker of inflammation. The findings from this study suggest that this combination treatment offers two advantages, preventing bacterial growth and reducing inflammation, making it a promising choice for skin breakouts. In addition, this combination was not toxic to fibroblasts, supporting its capacity as a safe skin treatment. Interestingly, at a 15:5:10 GM:CC:AE ratio, this combination treatment displayed high selectivity indices (SIs) against Staphylococcus epidermidis (26.87) and C. acnes (4.99), indicating its strong therapeutic potential without side effects. In conclusion, our study highlights that this combination is a novel, effective, and safe choice for controlling acne vulgaris, especially because of its ability to inhibit TOP2α and regulate NFκB1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.